New Varian/Accel Superconducting Cyclotron Enables Year-Round Proton Treatments at Leading European Research Institute
March 22 2007 - 4:00AM
PR Newswire (US)
VILLIGEN, Switzerland, March 22 /PRNewswire-FirstCall/ --
Clinicians at the Paul Scherrer Institute in Switzerland have begun
clinical treatments using the world's first commercial
superconducting cyclotron for routine medical use, enabling
high-precision proton therapy treatments for a range of cancer
patients. The new cyclotron from Varian Medical Systems' Accel
group is a key component of the equipment and is expected to
facilitate more accurate treatments with fewer side effects. Two
patients with chordomas - bone tumors in the spinal region - were
the first to be treated using protons generated by the new 250 MeV
cyclotron, which is designed for high efficiency, low energy
consumption, high reliability and modern treatment features such as
spot scanning, enabling highly effective proton dose distribution
in three dimensions, and beam intensity modulation. Dr. Martin
Jermann, head of the PROSCAN proton therapy program at the Paul
Scherrer Institute (PSI), said, "The first treatments went smoothly
and we intend to increase the number of patients treated per day to
ten over the next few weeks. The objective of such proton therapy
treatments is to cure the patients and to minimise both short-term
and long-term side effects." The Varian/Accel superconducting
cyclotron represents a dedicated proton source for the PSI
equipment, with beam-lines to supply up to 250 MeV protons to the
spot-scanning gantry for deep-seated tumor treatments. PSI operates
the world's first and only compact scanning gantry for proton
radiation therapy of deep-seated tumors. The spot-scanning
technique developed at PSI enables malignant tumours to be targeted
with high precision deep inside in the body, and their growth
successfully stopped, without damaging healthy tissue around the
target area. Protons have excellent physical properties for
radiation therapy, which enable clinicians to very precisely
control the shape of the dose distribution inside the patient's
body. The depth of the proton beam can be precisely controlled,
which means healthy tissue behind the tumor can be spared as
effectively as adjacent tissue. Dr. Jermann said that the new
cyclotron would allow the institute's proton therapy facility to
operate all year rather than being limited to just 6-8 months, as
was the case with the department's previous equipment. "In
addition, the beam characteristics and dynamics will allow the
development of advanced scanning features, which should enable us
to image and treat moving tumors in the lung and breast with
extremely high precision," he said. The Varian/Accel
superconducting cyclotron, degrader, beam line and gantries will
enable PSI to maintain and enhance its international reputation as
a unique high-tech laboratory for advanced proton therapy as well
as a leading clinical proton therapy research center. Dr. Jermann
added, "In future, 150-250 patients per year will benefit from
advances in deep-seated tumor therapy at PSI, in addition to the
200-300 eye cancer patients already being treated, with success
rates of more than 98 percent." Lester Boeh, vice president of
emerging businesses for Varian, said, "This is a real landmark for
our proton therapy business and good news for European cancer
patients. Varian/Accel's superconducting cyclotron enables proton
therapy to be delivered in the most accurate, effective and
efficient manner possible and we are delighted that treatments are
underway at PSI." About Varian Medical Systems Varian Medical
Systems, Inc., of Palo Alto, California, is the world's leading
manufacturer of medical devices and software for treating cancer
and other medical conditions with radiotherapy, radiosurgery,
proton therapy, and brachytherapy. The company supplies informatics
software for managing comprehensive cancer clinics, radiotherapy
centers and medical oncology practices. Varian is a premier
supplier of tubes and digital detectors for X- ray imaging in
medical, scientific, and industrial applications and also supplies
X-ray imaging products for cargo screening and industrial
inspection. Varian Medical Systems employs approximately 3,900
people who are located at manufacturing sites in North America and
Europe and in its 56 sales and support offices around the world. In
Europe, the company operates manufacturing and engineering centers
in Baden (Switzerland), Crawley (England), Haan (Germany), Helsinki
(Finland) and Toulouse (France) and has headquarters for Europe,
Middle East, India and Africa (EMEA) based in Zug, Switzerland. For
more information, visit http://www.varian.com/. About Paul Scherrer
Institute The Paul Scherrer Institute (PSI) is a multi-disciplinary
research centre for natural sciences and technology. In national
and international collaboration with universities, other research
institutes and industry, PSI is active in solid state physics,
materials sciences, elementary particle physics, life sciences,
nuclear and non-nuclear energy research, and energy- related
ecology. It is the largest research institute in Switzerland with
about 1,200 members of staff. Forward Looking Statements Statements
in this press release regarding future business, events, plans,
objectives, expectations, estimates, and other similar matters,
including, but not limited to, statements using the terms "can" and
"expect," constitute forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements contained in this press release are
subject to risks and uncertainties that could cause actual results
to differ materially from those anticipated, including, but not
limited to, the risks described in the company's Annual Report on
Form 10-K and other reports filed from time to time by the Company
with the Securities and Exchange Commission. These forward-looking
statements represent the Company's judgment as of the date of this
press release. The Company assumes no obligation to update or
revise these forward-looking statements because of new information,
future events, or otherwise. Neil Madle Varian Medical Systems +44
7786 526068, DATASOURCE: Varian Medical Systems CONTACT: Neil Madle
of Varian Medical Systems, +44 7786 526068, Web site:
http://www.varian.com/
Copyright